Skip to main content

Table 4 Adverse outcome measures examined in relation to frailty

From: Frailty and solid-organ transplant candidates: a scoping review

 

All

Heart [93,94,95,96,97,98]

Kidney [14, 19, 20, 25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49]

Liver [15, 58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86]

Lung [102,103,104,105,106,107,108,109,110,111,112,113,114,115,116]

Multiorgan [118,119,120]

# of studies examining at least one adverse outcome N (%)

74 (73.3)

6 (5.9)

25 (24.8)

28 (27.7)

11 (10.9)

4 (4.0)

# of studies examining each adverse outcome N

Mortality

29

5

6

9

5

4

Length of staya

20

4

4

5

5

2

Institutionalizationb

4

0

1

2

0

1

Complications post-surgery

9

0

3

4

1

1

Rehospitalizationc

4

0

2

1

1

0

Functional decline

4

0

1

1

1

1

Treatment changed

2

2

0

0

0

0

Delirium

1

0

1

0

0

0

Transplant rejectione

1

0

0

1

0

0

Cognitive decline

1

0

1

0

0

0

Quality of life decline

4

0

2

1

1

0

Transplant Status (i.e., Delisting)

17

3

6

5

2

1

Waitlist mortality

21

1

6

12

2

0

Other

18

1

10

4

3

0

  1. a Length of stay during transplant admission
  2. b Discharge to a care facility
  3. c Representation post-discharge after transplant
  4. d Additional procedure/treatment (e.g., Ventricular Assisted Device insertion)
  5. e Transplant rejection/acute cellular rejection